parkinson disease

Summary

Summary: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Top Publications

  1. pmc 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
    R Jeremy Nichols
    University of Dundee, Scotland, UK
    Biochem J 430:393-404. 2010
  2. ncbi Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
    R Kruger
    Nat Genet 18:106-8. 1998
  3. ncbi The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia
    Juan J Zarranz
    Department of Neurology, de Cruces Hospital, Departament of Neuroscience, University del Pais Vasco, Baracaldo, Vizcaya, Spain
    Ann Neurol 55:164-73. 2004
  4. pmc Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors
    Frank Soldner
    The Whitehead Institute, Cambridge Center, MA 02142, USA
    Cell 136:964-77. 2009
  5. ncbi Parkinsonism: onset, progression and mortality
    M M Hoehn
    Neurology 17:427-42. 1967
  6. doi Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease
    Wataru Satake
    Division of Neurology Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan
    Nat Genet 41:1303-7. 2009
  7. ncbi Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
    Coro Paisan-Ruiz
    Unitat de Genetica Molecular, Departament de Genòmica i Proteòmica, Institut de Biomedicina de València CSIC, E46010 Valencia, Spain
    Neuron 44:595-600. 2004
  8. pmc A MicroRNA feedback circuit in midbrain dopamine neurons
    Jongpil Kim
    Departments of Pathology and Neurology, Center for Neurobiology and Behavior, and Taub Institute, Columbia University, College of Physicians and Surgeons 15 403, 630 West 168th Street, New York, NY 10032, USA
    Science 317:1220-4. 2007
  9. ncbi Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
    H Shimura
    Department of Neurology, Juntendo University School of Medicine, Bunkyo ku, Tokyo, Japan
    Nat Genet 25:302-5. 2000
  10. pmc Parkin is recruited selectively to impaired mitochondria and promotes their autophagy
    Derek Narendra
    Biochemistry Section, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Cell Biol 183:795-803. 2008

Research Grants

  1. Divalent Metal Transporter: Role in Manganese Toxicity
    JEROME ROTH; Fiscal Year: 2004
  2. High Force Resistance Training and Dopamine Replacement Effects on Hypokinesia in
    LELAND DIBBLE; Fiscal Year: 2007
  3. Human embryonic stem cell-derived neural crest stem cells and Hirschsprung disea
    Sean J Morrison; Fiscal Year: 2010
  4. Exome re-sequencing candidate loci for familial essential tremor
    Barry E Kosofsky; Fiscal Year: 2012
  5. GI Endotoxin as an Environmental Trigger in an alpha-Synuclein Transgenic Mouse
    Robert L Nussbaum; Fiscal Year: 2012
  6. Samay Jain; Fiscal Year: 2015
  7. JOHN BRANNON GARY; Fiscal Year: 2014
  8. ERNESTO ROQUE BONGARZONE; Fiscal Year: 2016
  9. Improving Quality of Care in Parkinsons Disease: A Randomized Controlled Trial
    KAREN ILENE CONNOR; Fiscal Year: 2013
  10. Glucocerebrosidase mutations in a mouse synucleinopathy model
    Robert L Nussbaum; Fiscal Year: 2011

Detail Information

Publications439 found, 100 shown here

  1. pmc 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization
    R Jeremy Nichols
    University of Dundee, Scotland, UK
    Biochem J 430:393-404. 2010
    ..These results provide the first evidence suggesting that 14-3-3 regulates LRRK2 and that disruption of the interaction of LRRK2 with 14-3-3 may be linked to Parkinson's disease...
  2. ncbi Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease
    R Kruger
    Nat Genet 18:106-8. 1998
  3. ncbi The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia
    Juan J Zarranz
    Department of Neurology, de Cruces Hospital, Departament of Neuroscience, University del Pais Vasco, Baracaldo, Vizcaya, Spain
    Ann Neurol 55:164-73. 2004
    ..Our data show that, in addition to the previously described hereditary alpha-synucleinopathies, dementia with Lewy bodies is related to mutation of alpha-synuclein...
  4. pmc Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors
    Frank Soldner
    The Whitehead Institute, Cambridge Center, MA 02142, USA
    Cell 136:964-77. 2009
    ..Our results indicate that residual transgene expression in virus-carrying hiPSCs can affect their molecular characteristics and that factor-free hiPSCs therefore represent a more suitable source of cells for modeling of human disease...
  5. ncbi Parkinsonism: onset, progression and mortality
    M M Hoehn
    Neurology 17:427-42. 1967
  6. doi Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease
    Wataru Satake
    Division of Neurology Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan
    Nat Genet 41:1303-7. 2009
    ..Our results identify two new PD susceptibility loci, show involvement of autosomal dominant parkinsonism loci in typical PD and suggest that population differences contribute to genetic heterogeneity in PD...
  7. ncbi Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease
    Coro Paisan-Ruiz
    Unitat de Genetica Molecular, Departament de Genòmica i Proteòmica, Institut de Biomedicina de València CSIC, E46010 Valencia, Spain
    Neuron 44:595-600. 2004
    ..Because of the tremor observed in PD and because a number of the families are of Basque descent, we have named this protein dardarin, derived from the Basque word dardara, meaning tremor...
  8. pmc A MicroRNA feedback circuit in midbrain dopamine neurons
    Jongpil Kim
    Departments of Pathology and Neurology, Center for Neurobiology and Behavior, and Taub Institute, Columbia University, College of Physicians and Surgeons 15 403, 630 West 168th Street, New York, NY 10032, USA
    Science 317:1220-4. 2007
    ..We propose a role for this feedback circuit in the fine-tuning of dopaminergic behaviors such as locomotion...
  9. ncbi Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
    H Shimura
    Department of Neurology, Juntendo University School of Medicine, Bunkyo ku, Tokyo, Japan
    Nat Genet 25:302-5. 2000
    Autosomal recessive juvenile parkinsonism (AR-JP), one of the most common familial forms of Parkinson disease, is characterized by selective dopaminergic neural cell death and the absence of the Lewy body, a cytoplasmic inclusion body ..
  10. pmc Parkin is recruited selectively to impaired mitochondria and promotes their autophagy
    Derek Narendra
    Biochemistry Section, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA
    J Cell Biol 183:795-803. 2008
    ..These results show that Parkin promotes autophagy of damaged mitochondria and implicate a failure to eliminate dysfunctional mitochondria in the pathogenesis of Parkinson's disease...
  11. doi Parkinson's disease
    Andrew J Lees
    Department of Molecular Neuroscience and Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London and the National Hospital for Neurology and Neurosurgery, London, UK
    Lancet 373:2055-66. 2009
    ..Embryonic stem cells and gene therapy are promising research therapeutic approaches...
  12. pmc LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress
    Ha Nam Nguyen
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA 94305, USA
    Cell Stem Cell 8:267-80. 2011
    ..This enhanced stress sensitivity is consistent with existing understanding of early PD phenotypes and represents a potential therapeutic target...
  13. ncbi By carrot or by stick: cognitive reinforcement learning in parkinsonism
    Michael J Frank
    Department of Psychology and Center for Neuroscience, University of Colorado Boulder, Boulder, CO 80309 0345, USA
    Science 306:1940-3. 2004
    ....
  14. doi α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Lancet Neurol 10:230-40. 2011
    ..We aimed to assess whether reduction of α-synuclein concentrations in CSF was a marker for α-synuclein deposition in the brain, and therefore diagnostic of synucleinopathies...
  15. pmc A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death
    Kaoru Saijo
    Department of Cellular and Molecular Medicine, University of California, San Diego, 9500 Gilman Dr, La Jolla, California, CA 92093, USA
    Cell 137:47-59. 2009
    ..These studies suggest that Nurr1 protects against loss of dopaminergic neurons in Parkinson's disease in part by limiting the production of neurotoxic mediators by microglia and astrocytes...
  16. doi Neuroinflammation in Parkinson's disease: a target for neuroprotection?
    Etienne C Hirsch
    INSERM, UMRS 975, Centre de Recherche de l Institut du Cerveau et de la Moelle Epiniere, Experimental Therapeutics of Neurodegeneration, Paris, France
    Lancet Neurol 8:382-97. 2009
    ....
  17. pmc Autoregulation of Parkin activity through its ubiquitin-like domain
    Viduth K Chaugule
    Protein Structure and Function Laboratory, Cancer Research UK, London Research Institute, London, UK
    EMBO J 30:2853-67. 2011
    ..Our observations provide important molecular insights into the underlying basis of Parkinson's disease, and in the regulation of RBR E3-ligase activity...
  18. doi PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1
    Sven Geisler
    Laboratory of Functional Neurogenetics, Otfried Muller Strasse 27, 72076 Tubingen, Germany
    Nat Cell Biol 12:119-31. 2010
    ..Thus, our data provide functional links between PINK1, Parkin and the selective autophagy of mitochondria, which is implicated in the pathogenesis of Parkinson's disease...
  19. doi Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation
    Jia Yi Li
    Neuronal Survival Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, 221 84 Lund, Sweden
    Nat Med 14:501-3. 2008
    ..However, available data suggest that the majority of grafted cells are functionally unimpaired after a decade, and recipients can still experience long-term symptomatic relief...
  20. pmc Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis
    Venu M Nemani
    Departments of Neurology and Physiology, Graduate Program in Neuroscience, University of California, San Francisco, San Francisco, CA 94158, USA
    Neuron 65:66-79. 2010
    ..Increased levels of alpha-synuclein thus produce a specific, physiological defect in synaptic vesicle recycling that precedes detectable neuropathology...
  21. pmc Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy
    Nickie C Chan
    Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA
    Hum Mol Genet 20:1726-37. 2011
    ..These results indicate that remodeling of the mitochondrial outer membrane proteome is important for mitophagy, and reveal a causal link between the UPS and autophagy, the major pathways for degradation of intracellular substrates...
  22. pmc Genetic animal models of Parkinson's disease
    Ted M Dawson
    Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Neuron 66:646-61. 2010
    ..In this review, we discuss the animal models for these genetic causes of PD, their limitations, and value. Moreover, we discuss future directions and potential strategies for optimization of the genetic models...
  23. pmc Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease
    Taye H Hamza
    New York State Department of Health Wadsworth Center, Albany, New York, USA
    Nat Genet 42:781-5. 2010
    ..The genetic association with HLA supports the involvement of the immune system in Parkinson's disease and offers new targets for drug development...
  24. pmc Recent advances in the genetics of Parkinson's disease
    Ian Martin
    Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Annu Rev Genomics Hum Genet 12:301-25. 2011
    ..This, coupled with the established role of mitochondrial impairment in both familial and sporadic PD, highlights the likelihood of common mechanisms fundamental to the etiology of both...
  25. pmc Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization
    Nicolas Dzamko
    University of Dundee, Scotland, UK
    Biochem J 430:405-13. 2010
    ..They will also stimulate further research to understand how phosphorylation of Ser910 and Ser935 is controlled by LRRK2, and establish any relationship to development of Parkinson's disease...
  26. ncbi Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
    E R Dorsey
    Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Blvd, Suite 223, Rochester, NY 14620, USA
    Neurology 68:384-6. 2007
    ..published prevalence studies, we used two different methodologies to project the number of individuals with Parkinson disease (PD) in Western Europe's 5 most and the world's 10 most populous nations...
  27. pmc Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
    Daniel G Healy
    Department of Clinical Neurosciences, Institute of Neurology, University College London, London, UK
    Lancet Neurol 7:583-90. 2008
    ..LRRK2-associated PD be distinguished from idiopathic PD; which mutations in LRRK2 are pathogenic; and what is the age-specific cumulative risk of PD for individuals who inherit or are at risk of inheriting a deleterious mutation in LRRK2?..
  28. ncbi Staging of brain pathology related to sporadic Parkinson's disease
    Heiko Braak
    Department of Clinical Neuroanatomy, J W Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt Main, Germany
    Neurobiol Aging 24:197-211. 2003
    ..This study traces the course of the pathology in incidental and symptomatic Parkinson cases proposing a staging procedure based upon the readily recognizable topographical extent of the lesions...
  29. ncbi Stages in the development of Parkinson's disease-related pathology
    Heiko Braak
    Institute for Clinical Neuroanatomy, J W Goethe University, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    Cell Tissue Res 318:121-34. 2004
    ..At this point, most individuals probably cross the threshold to the symptomatic phase of the illness. In the end-stages 5-6, the process enters the mature neocortex, and the disease manifests itself in all of its clinical dimensions...
  30. ncbi Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease
    Wei Zhang
    Neuropharmacology Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences National Institutes of Health, Research Triangle Park, North Carolina, USA
    FASEB J 19:533-42. 2005
    ..Finally, NADPH oxidase could be an ideal target for potential pharmaceutical intervention, given that it plays a critical role in alpha-synuclein-mediated microglial activation and associated neurotoxicity...
  31. ncbi Pathological synchronization in Parkinson's disease: networks, models and treatments
    Constance Hammond
    Institut de Neurobiologie de la Mediterranee, U29 INSERM, Université Aix Marseille II and UMR CNRS 5543, Universite Bordeaux 2, France
    Trends Neurosci 30:357-64. 2007
    ..This review is part of the INMED/TINS special issue, Physiogenic and pathogenic oscillations: the beauty and the beast, based on presentations at the annual INMED/TINS symposium (http://inmednet.com/)...
  32. pmc PINK1 is selectively stabilized on impaired mitochondria to activate Parkin
    Derek P Narendra
    Biochemistry Section, Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    PLoS Biol 8:e1000298. 2010
    ..In addition, they support a novel model for the negative selection of damaged mitochondria, in which PINK1 signals mitochondrial dysfunction to Parkin, and Parkin promotes their elimination...
  33. ncbi Transplantation of embryonic dopamine neurons for severe Parkinson's disease
    C R Freed
    Division of Clinical Pharmacology, University of Colorado School of Medicine, Denver 80262, USA
    N Engl J Med 344:710-9. 2001
    ..CONCLUSIONS: Human embryonic dopamine-neuron transplants survive in patients with severe Parkinson's disease and result in some clinical benefit in younger but not in older patients...
  34. pmc Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus
    Michael J Devine
    MRC Centre for Regenerative Medicine, Institute for Stem Cell Research, University of Edinburgh, Edinburgh EH9 3JQ, UK
    Nat Commun 2:440. 2011
    ..This model represents a new experimental system to identify compounds that reduce levels of α-synuclein, and to investigate the mechanistic basis of neurodegeneration caused by α-synuclein dysfunction...
  35. pmc Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression
    Min Shi
    Department of Pathology, University of Washington School of Medicine, Seattle, 98104, USA
    Ann Neurol 69:570-80. 2011
    There is a clear need to develop biomarkers for Parkinson disease (PD) diagnosis, differential diagnosis of Parkinsonian disorders, and monitoring disease progression...
  36. pmc Genetic analysis of pathways to Parkinson disease
    John Hardy
    Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
    Neuron 68:201-6. 2010
    In this review I outline the arguments as to whether we should consider Parkinson disease one or more than one entity and discuss genetic findings from Mendelian and whole-genome association analysis in that context...
  37. pmc Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease
    Sonja Kriks
    Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA
    Nature 480:547-51. 2011
    ..Excellent DA neuron survival, function and lack of neural overgrowth in the three animal models indicate promise for the development of cell-based therapies in Parkinson's disease...
  38. pmc PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility
    Xinnan Wang
    F M Kirby Neurobiology Center, Children s Hospital Boston, Boston, MA 02115, USA
    Cell 147:893-906. 2011
    ..PINK1 has been shown to act upstream of Parkin, but the mechanism corresponding to this relationship has not been known. We propose that PINK1 phosphorylation of substrates triggers the subsequent action of Parkin and the proteasome...
  39. pmc Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1
    Jaime N Guzman
    Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Nature 468:696-700. 2010
    ..Because drugs approved for human use can antagonize calcium entry through L-type channels, these results point to a novel neuroprotective strategy for both idiopathic and familial forms of Parkinson's disease...
  40. pmc Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153
    Epaminondas Doxakis
    Basic Neurosciences Division, Biomedical Research Foundation of the Academy of Athens, Soranou Efesiou 4, Athens 11527, Greece
    J Biol Chem 285:12726-34. 2010
    ..biochemical studies have established a central role for alpha-synuclein accumulation in the pathogenesis of Parkinson disease. Here, two microRNAs, namely mir-7 and mir-153, have been identified to regulate alpha-synuclein levels post-..
  41. pmc Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression
    Stephan Gehrke
    Department of Pathology, Stanford University School of Medicine, Stanford, California 94305, USA
    Nature 466:637-41. 2010
    ..Our results implicate deregulated synthesis of E2F1/DP caused by the miRNA pathway impairment as a key event in LRRK2 pathogenesis and suggest novel miRNA-based therapeutic strategies...
  42. doi Parkinson's disease: from monogenic forms to genetic susceptibility factors
    Suzanne Lesage
    INSERM, UMR_S679, Paris, France
    Hum Mol Genet 18:R48-59. 2009
    ....
  43. pmc Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease
    Todd L Edwards
    John P Hussman Institute for Human Genomics, University of Miami, FL 33136, USA
    Ann Hum Genet 74:97-109. 2010
    b>Parkinson disease (PD) is a chronic neurodegenerative disorder with a cumulative prevalence of greater than one per thousand...
  44. pmc α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells
    Christian Hansen
    Neuronal Survival Unit, Wallenberg Neuroscience Center, Lund University, Lund, Sweden
    J Clin Invest 121:715-25. 2011
    Post-mortem analyses of brains from patients with Parkinson disease who received fetal mesencephalic transplants show that α-synuclein-containing (α-syn-containing) Lewy bodies gradually appear in grafted neurons...
  45. pmc Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission
    Ruben K Dagda
    Department of Pathology and Center for Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    J Biol Chem 284:13843-55. 2009
    Mitochondrial dysregulation is strongly implicated in Parkinson disease. Mutations in PTEN-induced kinase 1 (PINK1) are associated with familial parkinsonism and neuropsychiatric disorders...
  46. pmc Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein
    Xian Lin
    Unit of Transgenesis, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA
    Neuron 64:807-27. 2009
    ....
  47. ncbi Alpha-synuclein locus duplication as a cause of familial Parkinson's disease
    Marie Christine Chartier-Harlin
    Unité INSERM 508, 1 rue du Pr Calmette, BP 245, 59019 Lille Cedex, France
    Lancet 364:1167-9. 2004
    ..These findings suggest a direct relation between SNCA gene dosage and disease progression...
  48. ncbi Non-motor symptoms of Parkinson's disease: diagnosis and management
    K Ray Chaudhuri
    Movement Disorders Unit, Kings College Hospital, Guy s King s and St Thomas School of Medicine, London, UK
    Lancet Neurol 5:235-45. 2006
    ..Inevitably, the development of treatments that can slow or prevent the progression of Parkinson's disease and its multicentric neurodegeneration provides the best hope of curing non-motor symptoms...
  49. pmc Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
    Liya Qin
    Bowles Center for Alcohol Studies, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
    Glia 55:453-62. 2007
    ..These findings provide valuable insight into the potential pathogenesis and self-propelling nature of Parkinson's disease...
  50. doi Parkinson's disease: clinical features and diagnosis
    J Jankovic
    Department of Neurology, Parkinson s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, 6550 Fannin, Suite 1801, Houston, Texas 77030 3498, USA
    J Neurol Neurosurg Psychiatry 79:368-76. 2008
    ..This review describes the clinical characteristics of PD with emphasis on those features that differentiate the disease from other parkinsonian disorders...
  51. doi Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease
    Jeffrey H Kordower
    Department of Neurological Sciences and Center for Brain Repair, Rush University Medical Center, 1735 West Harrison Street, Chicago, Illinois 60612, USA
    Nat Med 14:504-6. 2008
    ..These findings have implications for cell-based therapies and for understanding the cause of Parkinson's disease...
  52. doi Metals, oxidative stress and neurodegenerative disorders
    Klaudia Jomova
    Department of Chemistry, Faculty of Natural Sciences, Constantine the Philosopher University, SK 949 74, Nitra, Slovakia
    Mol Cell Biochem 345:91-104. 2010
    ..An alternate hypothesis topic in AD is also discussed...
  53. ncbi Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA
    Science 317:516-9. 2007
    ..Furthermore, the inhibitors protected against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease. The results suggest a link between neurodegeneration and aging...
  54. doi Systematic review of levodopa dose equivalency reporting in Parkinson's disease
    Claire L Tomlinson
    Birmingham Clinical Trials Unit, University of Birmingham, Edgbaston, Birmingham, United Kingdom
    Mov Disord 25:2649-53. 2010
    ..Using these conversion formulae to report LEDs would improve the consistency of reporting and assist the interpretation of clinical trials comparing different PD medications...
  55. doi Missing pieces in the Parkinson's disease puzzle
    Jose A Obeso
    Department of Neurology, Clínica Universitaria and Medical School of Navarra, Neuroscience Centre, Center for Applied Medical Research, Pamplona, Spain
    Nat Med 16:653-61. 2010
    ..Here we discuss a series of critical issues that we think researchers need to address to stand a better chance of solving the different challenges posed by this pathology...
  56. doi The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years
    Mariese A Hely
    Department of Neurology, Westmead Hospital, Westmead, New South Wales, Australia
    Mov Disord 23:837-44. 2008
    ..The challenge is to understand the cellular mechanisms underlying the diverse features of advanced PD that go far beyond a lack of dopamine...
  57. pmc α-Synuclein impairs macroautophagy: implications for Parkinson's disease
    Ashley R Winslow
    Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, England, UK
    J Cell Biol 190:1023-37. 2010
    ..Rab1a, α-synuclein, and Atg9 all regulate formation of the omegasome, which marks autophagosome precursors...
  58. ncbi A randomized trial of deep-brain stimulation for Parkinson's disease
    Gunther Deuschl
    Christian Albrechts University, Kiel, Germany
    N Engl J Med 355:896-908. 2006
    ..Neurostimulation of the subthalamic nucleus reduces levodopa-related motor complications in advanced Parkinson's disease. We compared this treatment plus medication with medical management...
  59. pmc The PINK1/Parkin pathway regulates mitochondrial morphology
    Angela C Poole
    Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 105:1638-43. 2008
    ..Our studies suggest that the PINK1/Parkin pathway promotes mitochondrial fission and that the loss of mitochondrial and tissue integrity in PINK1 and parkin mutants derives from reduced mitochondrial fission...
  60. pmc Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
    Byoung Dae Lee
    Neuroregeneration Program, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Nat Med 16:998-1000. 2010
    ..These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease...
  61. pmc Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21
    Chris C A Spencer
    Wellcome Trust Centre for Human Genetics, Oxford, UK
    Hum Mol Genet 20:345-53. 2011
    ..We found no support for the previously reported SNP association in 12q12/LRRK2. We also found an association of the two SNPs in 4q22/SNCA with the age of onset of the disease...
  62. pmc PINK1-dependent recruitment of Parkin to mitochondria in mitophagy
    Cristofol Vives-Bauza
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 107:378-83. 2010
    ..Thus by impairing this process, mutations in either Parkin or PINK1 may alter mitochondrial turnover which, in turn, may cause the accumulation of defective mitochondria and, ultimately, neurodegeneration in Parkinson's disease...
  63. pmc PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65
    Chandana Kondapalli
    MRC Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dundee DD1 5EH, UK
    Open Biol 2:120080. 2012
    ..Our findings also suggest that small molecule activators of Parkin that mimic the effect of PINK1 phosphorylation may confer therapeutic benefit for PD...
  64. pmc Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells
    Kelvin C Luk
    Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Center for Neurodegenerative Disease Research, Institute on Aging, Philadelphia, PA 19104 4283, USA
    Proc Natl Acad Sci U S A 106:20051-6. 2009
    ....
  65. doi The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease
    Pablo Martinez-Martin
    Area of Applied Epidemiology, National Centre of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain
    Mov Disord 26:399-406. 2011
    ..In this study, the Non-Motor Symptoms Scale (NMSS) was used to assess the impact of the non-motor symptoms on HRQoL of Parkinson's disease patients...
  66. doi Epidemiology and etiology of Parkinson's disease: a review of the evidence
    Karin Wirdefeldt
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Eur J Epidemiol 26:S1-58. 2011
    ..Future epidemiologic studies of PD should be large, include detailed quantifications of exposure, and collect information on environmental exposures as well as genetic polymorphisms...
  67. pmc Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells
    Edward D Plowey
    Department of Pathology, Division of Neuropathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    J Neurochem 105:1048-56. 2008
    ..These results indicate an active role for autophagy in neurite remodeling induced by pathogenic mutation of LRRK2...
  68. pmc Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease
    Yanping Li
    Department of Neurology and Neurosciences, Weill Medical College of Cornell University, New York, New York, USA
    Nat Neurosci 12:826-8. 2009
    ..These mice provide a valid model of Parkinson's disease and are a resource for the investigation of pathogenesis and therapeutics...
  69. ncbi Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena
    Bastiaan R Bloem
    Department of Neurology, University Medical Centre St Radboud, Nijmegen, The Netherlands
    Mov Disord 19:871-84. 2004
    ....
  70. pmc Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats
    Gunnar Hargus
    Udall Parkinson s Disease Research Center of Excellence, McLean Hospital Harvard Medical School, Belmont, MA 02478, USA
    Proc Natl Acad Sci U S A 107:15921-6. 2010
    ....
  71. pmc DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy
    Kelly Jean Thomas
    Laboratory of Neurogenetics, National Institute on Aging, Flow Cytometry Core Facility, National Institutes of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20982 3707, USA
    Hum Mol Genet 20:40-50. 2011
    ..None of the three proteins complex together using size exclusion chromatography. These data suggest that DJ-1 works in parallel to the PINK1/parkin pathway to maintain mitochondrial function in the presence of an oxidative environment...
  72. pmc Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants
    Jessica C Greene
    Department of Genome Sciences, University of Washington, P O Box 357730, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 100:4078-83. 2003
    ....
  73. ncbi Molecular pathways of neurodegeneration in Parkinson's disease
    Ted M Dawson
    Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Science 302:819-22. 2003
    ..Strategies aimed at restoring complex I activity, reducing oxidative stress and alpha-synuclein aggregation, and enhancing protein degradation may hold particular promise as powerful neuroprotective agents in the treatment of PD...
  74. ncbi Parkinson's disease: mechanisms and models
    William Dauer
    Department of Neurology, Columbia University, New York, NY 10032, USA
    Neuron 39:889-909. 2003
    ..PD models based on the manipulation of PD genes should prove valuable in elucidating important aspects of the disease, such as selective vulnerability of substantia nigra dopaminergic neurons to the degenerative process...
  75. doi Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Mov Disord 27:8-30. 2012
    ....
  76. pmc A novel α-synuclein missense mutation in Parkinson disease
    Christos Proukakis
    Department of Clinical Neuroscience, University College London, UK
    Neurology 80:1062-4. 2013
    Alpha-synuclein (SNCA) is central to the pathogenesis of Parkinson disease (PD), with 3 missense mutations reported to date. We report a novel mutation (p.H50Q) in a pathologically proven case.
  77. ncbi In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
    Alexander Gerhard
    MRC Clinical Sciences Centre and Division of Neuroscience, Faculty of Medicine, Imperial College, London, UK
    Neurobiol Dis 21:404-12. 2006
    ..The absence of significant longitudinal changes suggests that microglia are activated early in the disease process, and levels then remain relatively static, possibly driving the disease via cytokine release...
  78. ncbi Oxidative stress in Parkinson's disease
    Peter Jenner
    Neurodegenerative Diseases Research Centre, GKT School of Biomedical Sciences, King s College, London, United Kingdom
    Ann Neurol 53:S26-36; discussion S36-8. 2003
    ....
  79. pmc Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
    Andrew B West
    Institute for Cell Engineering, Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Proc Natl Acad Sci U S A 102:16842-7. 2005
    ..These results suggest a gain-of-function mechanism for LRRK2-linked disease with a central role for kinase activity in the development of PD...
  80. pmc LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity
    Mahaboobi Jaleel
    MRC Protein Phosphorylation Unit, MSI WTB complex, University of Dundee, Dow Street, Dundee DD1 5EH, Scotland, UK
    Biochem J 405:307-17. 2007
    ..The results of the present study suggest that moesin, ezrin and radixin may be LRRK2 substrates, findings that have been exploited to develop the first robust quantitative assay to measure LRRK2 kinase activity...
  81. ncbi Epidemiology of Parkinson's disease
    Lonneke M L de Lau
    Department of Epidemiology and Biostatistics, Erasmus Medical Centre Rotterdam, Netherlands
    Lancet Neurol 5:525-35. 2006
    ..In this article, we review what is known about the prevalence, incidence, risk factors, and prognosis of PD from epidemiological studies...
  82. pmc PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy
    Noriyuki Matsuda
    Laboratory of Frontier Science, Tokyo Metropolitan Institute of Medical Science, Setagaya Ku, Tokyo 156 8506, Japan
    J Cell Biol 189:211-21. 2010
    ..Some pathogenic mutations of PINK1 and Parkin interfere with the aforementioned events, suggesting an etiological importance. These results provide crucial insight into the pathogenic mechanisms of PD...
  83. pmc PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease
    Joo Ho Shin
    Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cell 144:689-702. 2011
    ..The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation...
  84. doi Direct generation of functional dopaminergic neurons from mouse and human fibroblasts
    Massimiliano Caiazzo
    Stem Cells and Neurogenesis Unit, Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy
    Nature 476:224-7. 2011
    ..Direct generation of iDA cells from somatic cells might have significant implications for understanding critical processes for neuronal development, in vitro disease modelling and cell replacement therapies...
  85. pmc A mitochondrial etiology of Alzheimer and Parkinson disease
    Pinar Coskun
    Department of Biological Chemistry, Hewitt Hall, Irvine, CA 92697 3940, USA
    Biochim Biophys Acta 1820:553-64. 2012
    The genetics and pathophysiology of Alzheimer Disease (AD) and Parkinson Disease (PD) appears complex. However, mitochondrial dysfunction is a common observation in these and other neurodegenerative diseases.
  86. pmc The neuropathology of genetic Parkinson's disease
    Markos Poulopoulos
    Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Mov Disord 27:831-42. 2012
    ..In particular, there is a need for larger, unbiased pathological studies. Differential association of Lewy pathology with specific mutations may reflect heterogeneity in pathogenic mechanisms among the different PD-related genes...
  87. pmc Genomewide association study for susceptibility genes contributing to familial Parkinson disease
    Nathan Pankratz
    Indiana University School of Medicine, Health Information and Translational Sciences Building, Indianapolis, IN 46202 3002, USA
    Hum Genet 124:593-605. 2009
    Five genes have been identified that contribute to Mendelian forms of Parkinson disease (PD); however, mutations have been found in fewer than 5% of patients, suggesting that additional genes contribute to disease risk...
  88. pmc Striding out with Parkinson disease: evidence-based physical therapy for gait disorders
    Meg E Morris
    Melbourne School of Health Sciences, The University of Melbourne, Victoria, Melbourne 3010, Australia
    Phys Ther 90:280-8. 2010
    Although Parkinson disease (PD) is common throughout the world, the evidence for physical therapy interventions that enable long-term improvement in walking is still emerging...
  89. ncbi Hereditary early-onset Parkinson's disease caused by mutations in PINK1
    Enza Maria Valente
    CSS IRCCS, Mendel Institute, Viale Regina Margherita 261, 00198 Rome, Italy
    Science 304:1158-60. 2004
    ..These data provide a direct molecular link between mitochondria and the pathogenesis of PD...
  90. ncbi Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease
    Alessandro Stefani
    1IRCCS Fondazione St Lucia, 2Clinica Neurologica, Dipartimento di Neuroscienze, Universita di Roma Tor Vergata, Italy
    Brain 130:1596-607. 2007
    ..This combination of targets may also prove useful in extra-pyramidal disorders, such as progressive supranuclear palsy, for which treatments are currently elusive...
  91. pmc Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention
    MALU G TANSEY
    Department of Physiology, Emory University School of Medicine, 615 Michael Street, Atlanta, GA 30324, USA
    Neurobiol Dis 37:510-8. 2010
    ....
  92. pmc Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S
    Xianting Li
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Neurosci 30:1788-97. 2010
    ..The PD-associated mutation G2019S may exert pathogenic effects by impairing these functions of LRRK2. Our LRRK2 BAC transgenic mice, therefore, could provide a useful model for understanding early PD pathological events...
  93. ncbi Separating storage from retrieval dysfunction of temporal memory in Parkinson's disease
    Chara Malapani
    Department of Psychiatry and NYSPI, Columbia University, New York, NY 10032, USA
    J Cogn Neurosci 14:311-22. 2002
    ..Whether those two separable patterns of dysfunction in storing and retrieving temporal memories rely on distinct neural networks within the basal ganglia and/or their cortical targets remains to be answered by future research...
  94. pmc A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease
    Alexander Zimprich
    Department of Neurology, Medizinische Universität Wien, Vienna, Austria
    Am J Hum Genet 89:168-75. 2011
    To identify rare causal variants in late-onset Parkinson disease (PD), we investigated an Austrian family with 16 affected individuals by exome sequencing. We found a missense mutation, c.1858G>A (p...
  95. pmc Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress
    Clement A Gautier
    Center for Neurologic Diseases, Brigham and Women s Hospital, Program in Neuroscience, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:11364-9. 2008
    ....
  96. pmc Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease
    Vanessa Brochard
    INSERM, UMR S679, Experimental Neurology and Therapeutics, Hopital de la Salpetriere, Paris, France
    J Clin Invest 119:182-92. 2009
    b>Parkinson disease (PD) is a neurodegenerative disorder characterized by a loss of dopamine-containing neurons. Mounting evidence suggests that dopaminergic cell death is influenced by the innate immune system...
  97. pmc Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease
    E Sidransky
    Section on Molecular Neurogenetics, Medical Genetics Branch, NHGRI, National Institutes of Health, Bethesda, MD 20892 3708, USA
    N Engl J Med 361:1651-61. 2009
    ..We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease...
  98. ncbi Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin
    Nicole Exner
    Center for Integrated Protein Science Munich and Adolf Butenandt Institute, Department of Biochemistry, Laboratory for Alzheimer s and Parkinson s Disease Research, Ludwig Maximilians University, 80336 Munich, Germany
    J Neurosci 27:12413-8. 2007
    ..Our results may therefore suggest that PINK1 deficiency in humans results in mitochondrial abnormalities associated with cellular stress, a pathological phenotype, which can be ameliorated by enhanced expression of parkin...
  99. doi Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results
    Christopher G Goetz
    Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA
    Mov Disord 23:2129-70. 2008
    ..90 for each part), which support the use of sum scores for each part in preference to a total score of all parts. The combined clinimetric results of this study support the validity of the MDS-UPDRS for rating PD...
  100. pmc VPS35 mutations in Parkinson disease
    Carles Vilariño-Güell
    Department of Medical Genetics, University of British Columbia, Vancouver, Canada
    Am J Hum Genet 89:162-7. 2011
    ..of next-generation sequencing technologies to a Swiss kindred presenting with autosomal-dominant, late-onset Parkinson disease (PD). The family has tremor-predominant dopa-responsive parkinsonism with a mean onset of 50.6 ± 7.3 years...
  101. pmc Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database
    Christina M Lill
    Neuropsychiatric Genetics Group, Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany
    PLoS Genet 8:e1002548. 2012
    ..Our study provides an exhaustive and up-to-date summary of the status of PD genetics research that can be readily scaled to include the results of future large-scale genetics projects, including next-generation sequencing studies...

Research Grants81

  1. Divalent Metal Transporter: Role in Manganese Toxicity
    JEROME ROTH; Fiscal Year: 2004
    ..linked to development of severe and irreversible neurological disorders as well as increased risk to develop Parkinson disease. Although the mechanisms by which these metals induce neuronal cell death are not well defined, ..
  2. High Force Resistance Training and Dopamine Replacement Effects on Hypokinesia in
    LELAND DIBBLE; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): Idiopathic Parkinson disease (IPD) is the model movement disorder to explore the motor function of the basal ganglia...
  3. Human embryonic stem cell-derived neural crest stem cells and Hirschsprung disea
    Sean J Morrison; Fiscal Year: 2010
    ..Disease/therapy</keyword;keyword>Neurons/*transplantation</keyword;keyword>Parkinson Disease/therapy</keyword;keyword>Rats</keyword;keyword>Recovery of Function</keyword;keyword>..
  4. Exome re-sequencing candidate loci for familial essential tremor
    Barry E Kosofsky; Fiscal Year: 2012
    ..Studying the untoward effects of mutant ET genes will increase our knowledge of ET and other movement disorders such as Parkinson disease.
  5. GI Endotoxin as an Environmental Trigger in an alpha-Synuclein Transgenic Mouse
    Robert L Nussbaum; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Parkinson Disease (PD) is a common neurodegenerative disease affecting ~1 million people in the United States...
  6. Samay Jain; Fiscal Year: 2015
    ..with funding through the KL2/K12 mechanism for a proposal entitled, "Improving diagnosis and treatment of Parkinson disease with assessments of non-motor features by clinical and physiologic measures...
  7. JOHN BRANNON GARY; Fiscal Year: 2014
    ..In recent studies, the tyrosine enzyme has been linked to Parkinson disease and other neurodegenerative disease...
  8. ERNESTO ROQUE BONGARZONE; Fiscal Year: 2016
    ..deficits in several neurodegenerative disorders, including multiple sclerosis, Alzheimer disease, Parkinson disease and others. Our preliminary studies provide evidence that Krabbe disease is compounded by axonal defects...
  9. Improving Quality of Care in Parkinsons Disease: A Randomized Controlled Trial
    KAREN ILENE CONNOR; Fiscal Year: 2013
    ....
  10. Glucocerebrosidase mutations in a mouse synucleinopathy model
    Robert L Nussbaum; Fiscal Year: 2011
    b>Parkinson Disease (PD) is a common, mostly sporadic neurodegenerative disease of the central and autonomic nervous systems affecting ~1 million people in the United States...
  11. A Phase II Trial of Levodopa in Angelman Syndrome
    Wen Hann Tan; Fiscal Year: 2013
    ..the Preschool Language Scale, the Aberrant Behavior Checklist, as well as a modified version of the Unified Parkinson Disease Rating Scale...
  12. Role of complement in alpha-synuclein based models of Parkinson disease
    HEATHER ELIZABETH ALLEN; Fiscal Year: 2013
    ..the contribution of the complement system to pathology in an alpha- synuclein based, mouse model of Parkinson disease (PD)...
  13. Paula C Bickford; Fiscal Year: 2016
    ..If these therapies have significant clinical potential this will be a step forward for Parkinsons therapeutics. ..
  14. Rachel Saunders-Pullman; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): Developing strategies to identify individuals at risk for Parkinson disease (PD) and interventions to prevent its onset may be the best hope for reducing the disease burden...
  15. Scheduled and Responsive Brain Stimulation for the Treatment of Tourette Syndrome
    Michael S Okun; Fiscal Year: 2010
    ..Although DBS has been utilized for addressing basal ganglia disorders such as Parkinson disease, essential tremor, and dystonia, these diseases differ fundamentally from TS...
  16. Allison Hubel; Fiscal Year: 2014
    ..limb ischemia), chronic obstructive pulmonary disease, nervous system disorders (multiple sclerosis, Parkinson Disease, spinal cord injury), kidney diseases and more. Current methods for the preservation of MSCs are suboptimal...
  17. Cytokine Effects on Amphetamine-Induced Dopamine Release using PET Neuroimaging
    Jennifer C Felger; Fiscal Year: 2011
    ..To accomplish her goals, the applicants training plan will include a combination of mentored research, coursework, seminars, and attendance at national and international meetings. ..
  18. Full Human Genome Sequencing in ALS
    Robert H Brown; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): The causes of most neurodegenerative disorders (ALS, Alzheimer and Parkinson disease) are poorly understood, despite remarkable advances in delineating the molecular pathology in the rare forms of ..
  19. Glyn Dawson; Fiscal Year: 2015
    ..The impact of this research will be to better understand how sphingolipids work so that combination drug therapies can be used to treat patients in the future. ..
  20. High Sensitivity Mobile PET for Brain Imaging and Proton Therapy Monitoring
    Georges El Fakhri; Fiscal Year: 2010
    ..beam and radionuclide therapies, PET imaging in neurodegenerative diseases such as Alzheimer's disease, Parkinson Disease with Dementia and Lewy Body Dementia, in movement disorders and in psychiatric disorders such as obsessive ..
  21. Nicholas Muzyczka; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): One of the key problems in Parkinson Disease (PD) genetics is that mouse transgenic models have often not recapitulated what is seen in humans...
  22. The Role of the Intrinsic Apoptotic Pathway in Familial ALS
    Nichole Reyes; Fiscal Year: 2010
    ..number of important neurodegenerative diseases affecting our aging population, including Alzheimer disease, Parkinson disease, and Amyotrophic Lateral Sclerosis (ALS)...
  23. Spinocerebellar Ataxia Type 2 Gene and Gene Product
    Stefan M Pulst; Fiscal Year: 2013
    ..Mutations in the SCA2 (ATXN2) gene can also cause or contribute to the development of Parkinson disease and ALS, two common forms of neurodegeneration...
  24. NATALIA MOROZOVA PALACIOS; Fiscal Year: 2014
    ..outcomes and almost no work has been done to determine if air pollution could contribute to risk of Parkinson disease. For the majority of PD patients, environmental factors are believed to contribute substantially to risk of ..
  25. Investigating Neuroprotective Targets for Parkinson Disease Associated with Autop
    Guy A Caldwell; Fiscal Year: 2011
    DESCRIPTION (provided by applicant): Therapeutic advances to treat Parkinson disease (PD) are incumbent upon the identification and mechanistic understanding of cellular factors that influence neuronal survival...
  26. Does Intensive Voice Therapy Improve Airway Protection in Parkinsons Disease
    MICHAEL J HAMMER; Fiscal Year: 2012
    ....
  27. Identification of Novel Small Molecules as Tau Protein Aggregation Inhibitors for
    ALAN D SNOW; Fiscal Year: 2011
    ..of them found to be potent inhibitors of protein/peptide aggregates that are of central importance for AD, Parkinson disease and systemic AA amyloidosis...
  28. Allison Willis; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): Parkinson Disease (PD) is a common neurodegenerative disease of the elderly characterized by motor, cognitive, psychiatric and autonomic features, for which there is no cure...
  29. Jeffery Marvin Vance; Fiscal Year: 2015
    ..to identify genes or genetic mechanisms that cause or contribute to an individual's susceptibility to Parkinson Disease (PD) and to translate these discoveries into early detection of risk or disease, as well as provide ..
  30. miRNAs as regulators of gene expression in Parkinson Disease
    Kai Christian Sonntag; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Parkinson disease (PD) is caused by a progressive loss of the dopamine (DA) neurons in the substantia nigra pars compacta (SNc)...
  31. PET STUDY OF BIOCHEMISTRY AND METABOLISM OF THE CNS
    Kirk A Frey; Fiscal Year: 2012
    ..a Program Project with research plan focused on neurochemical positron emission tomography (PET) studies of Parkinson disease (PD)...
  32. Solomon Gilbert Diamond; Fiscal Year: 2014
    ..also be used to study neurovascular function in epilepsy for patients with implanted electrode arrays and in Parkinson disease for patients with implanted deep brain stimulation devices...
  33. KATHRYN ANNE CHUNG; Fiscal Year: 2014
    ..Levodopa induced dyskinesias (LID) are involuntary, abnormal movements that occur in most patients with Parkinson disease(PD) as a consequence of chronic use of the most effective symptomatic drug, levodopa (LD)...
  34. Synaptic processing in the basal ganglia
    David J Perkel; Fiscal Year: 2012
    ..cognitive function, because a variety of disorders such as autism spectrum disorder, schizophrenia, Parkinson disease and Huntington disease involve the basal ganglia, this research also has the potential to have long- term ..
  35. Nigrostriatal Dopamine Function
    JAMES TEPPER; Fiscal Year: 2009
    ..In addition, these mice afford a novel way to study the electrophysiological and anatomical properties of novel populations of striatal interneurons that have been very difficult or impossible to study previously. ..
  36. Identification of a Novel Gene for Parkinson Disease
    Han Xiang Deng; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Parkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease...
  37. NEUROPATHOLOGY OF CHRONIC MANGANESE EXPOSURE
    Brad A Racette; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Parkinson disease (PD) is a common neurodegenerative disorder affecting more than 1 million people in North America...
  38. Pathophysiology of dystonia: animal models
    Ellen J Hess; Fiscal Year: 2010
    ..Unlike Parkinson disease or Huntington disease where cell death provides clues to the pathogenesis of the movement disorder, dystonia ..
  39. Role of oligomeric alpha-synuclein in synucleinopathies
    Pamela J McLean; Fiscal Year: 2013
    ..that alpha-synuclein (1syn) accumulation is an early step in the development of both sporadic and inherited Parkinson disease (PD)...
  40. Medication Use, Cormobidity and Outcomes in Aging Populations
    Robert J Glynn; Fiscal Year: 2010
    ..A particular focus is on the impact of common, symptomatic conditions, including depression, Parkinson disease, and chronic obstructive lung disease, on use of preventive therapies, including glaucoma drugs, bone ..
  41. JAIME A KAMINER; Fiscal Year: 2014
    ..abstract_text> ..
  42. Characterization of the role of cyclin G-associated kinase in Parkinson disease
    Richard H Myers; Fiscal Year: 2013
    ..These PD investigators are uniquely experienced with the GAK gene and region and have already in hand all the samples needed to carry out these definitive studies. ..
  43. Animal models to study iron homeostasis
    Ruben Vidal; Fiscal Year: 2010
    ..regions that undergo degeneration in several neurodegenerative diseases such as Alzheimer disease (AD) and Parkinson disease (PD) (1-3). However, the precise role of iron in the neurodegenerative process is unclear...
  44. H5N1 Influenza Virus as a Novel Etiological Agent in Parkinsons Disease
    Richard J Smeyne; Fiscal Year: 2010
    ..Here, he writes " ...we would do well to reawaken ourselves to what may be a formidable threat not only to human lives, but also to the human brain in those who will survive an H5N1 influenza infection". ..
  45. DANIEL OLIVER CLAASSEN; Fiscal Year: 2016
    PROJECT SUMMARY Dopamine (DA) therapy used for the treatment of Parkinson Disease (PD) consists of Levodopa and Dopamine receptor Agonist (DAA) medications...
  46. Robert Folmer; Fiscal Year: 2015
    DESCRIPTION (provided by applicant): Few investigations of auditory function in patients with Parkinson Disease (PD) have been conducted or published...
  47. Amy L Wilson-Delfosse; Fiscal Year: 2014
    ..abstract_text> ..
  48. Stephen L Hauser; Fiscal Year: 2016
    ..g.-Alzheimer disease, stroke, epilepsy, Parkinson disease) have increased dramatically...
  49. Novel MRI Methods for Neuronal Loss and Iron Quantification in Parkinsons Disease
    Shalom Michaeli; Fiscal Year: 2010
    ....
  50. Mechanisms of Selective Neurodegeneration in Parkinson Disease
    Xugang Xia; Fiscal Year: 2010
    ..The results from these studies would advance the understanding on the disease mechanisms and would guide the development of PD therapy. ..
  51. The Role of Ikappa-B Kinase and Glycogen Synthase Kinase 3-beta in Axon Degenerat
    Josiah Gerdts; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): In several neurologic disorders including Alzhemier disease, Parkinson disease, and diabetic neuropathy, axonopathy contributes significantly to morbidity and disease progression...
  52. MONTHAPORN S BRYANT; Fiscal Year: 2015
    ..In summary, care and quality of life in Veterans living with PD will be improved. ..
  53. Efficacy of Voice Treatment for Parkinson's Disease
    Lorraine O Ramig; Fiscal Year: 2011
    ..At least 89% of the nearly seven million individuals diagnosed with idiopathic Parkinson disease (IPD) worldwide have a speech or voice disorder, yet only 3-4% receive speech treatment...
  54. The Cellular and Molecular Mechanisms of Parkinson's Disease
    FREDERICK CHARLES NUCIFORA; Fiscal Year: 2012
    ..Mutation in the leucine-rich repeat kinase-2 (LRRK2) gene is the most common known familial cause of Parkinson disease (PD) and also a cause of sporatic PD...
  55. Anthony J Baucum; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Parkinson disease (PD) is proximally caused by degeneration of dopamine containing neurons that project from the Substantial Nigra to the striatum...
  56. NIKOLAUS RENZ MCFARLAND; Fiscal Year: 2014
    ..Alpha- synuclein ([unreadable]Syn) is a principal component of Lewy bodies found pathologically in Parkinson disease (PD) and related disorders, such as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA)...
  57. NICOLAAS IDA BOHNEN; Fiscal Year: 2014
    DESCRIPTION (provided by applicant): Olfactory dysfunction is common in Parkinson disease (PD) and has been attributed to early deposition of a-synuclein pathology in the olfactory bulb...
  58. Risk Factors for Pathologic Markers of Parkinson Disease
    GEORGE WEBSTER ROSS; Fiscal Year: 2010
    ..This will also provide opportunity to examine the influence of a wider age range, as well as additional occupational, dietary, medical, constitutional, and environmental exposures on SN neuron density and striatal dopamine levels. ..
  59. Dopaminergic Modulation Of Cognitive Aspects Of Skill Acquisition In PD
    Brenda Hanna Pladdy; Fiscal Year: 2010
    b>Parkinson disease (PD) is characterized by cardinal symptoms of bradykinesia, rigidity, and resting tremor considered reflective of dopaminergic (DA) neuronal loss in the nigrostriatal tract...
  60. J Timothy Greenamyre; Fiscal Year: 2015
    ..to rotenone chronically, they develop selective degeneration of the nigrostriatal dopamine system similar to Parkinson disease. The molecular and physiological basis for such heterogeneity in biological response is obscure and no ..
  61. PKC-beta Regulation of the Dopmaine Transporter Trafficking
    Rong Chen; Fiscal Year: 2010
    ..Dysfunctional DAT has been implicated in neurodegenerative and neuropsychiatric disorders such as Parkinson disease, schizophrenia, attention deficit and hyperactivity disorder, and drug addiction...
  62. Psychophysiology of Emotion in Parkinsons Disease
    JENNA B DIETZ; Fiscal Year: 2013
    ..findings from this study may suggest a framework for viewing motivational deficits in patients with Parkinson disease, including commonly occurring neuropsychiatric symptoms such as apathy...
  63. Roy Alcalay; Fiscal Year: 2016
    ..Mutations in glucocerebrosidase (GBA) are among the most common identifiable genetic risk factors for Parkinson disease (PD), with a frequency >3% in PD patients who are not Ashkenazi Jewish (AJ) and >15% in AJ PD patients...
  64. Limited Competition for Continuation of the NIH Exploratory Trials in PD
    Oksana Suchowersky; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Parkinson disease (PD) is a progressive neurodegenerative disorder affecting 3/100 people over the age of 65. There is no cure and etiology is unknown...
  65. Glucocerebrosidase mutations in a mouse synucleinopathy model
    Robert L Nussbaum; Fiscal Year: 2010
    b>Parkinson Disease (PD) is a common, mostly sporadic neurodegenerative disease of the central and autonomic nervous systems affecting ~1 million people in the United States...
  66. Significance of Caspase-Mediated Cleavage of PARP-1 in Cell Death
    KAREN DAVID; Fiscal Year: 2007
    ..in experimental models of ischemia- reperfusion injury, myocardial infarction, glutamate excitotoxicity, and Parkinson disease. Thus, PARP-1 inhibition has been a therapeutic focus for aging-related diseases such as stroke, heart ..
  67. Defective nuclear FGFR1 signaling - a new model for PD
    MICHAL STACHOWIAK; Fiscal Year: 2003
    In Parkinson Disease (PD) the content of fibroblast growth factor-2 (FGF-2) in dopamine neurons in substantia nigra pars compacta (Snc) becomes depleted prior to cell degeneration...
  68. Virtual Therapist Speech Treatment for Parkinson Disease
    RONALD COLE; Fiscal Year: 2005
    ..first short- and long-term experimental efficacy data for speech treatment for individuals with Idiopathic Parkinson disease (IPD), documenting acoustic, aerodynamic and physiologic changes accompanying treatment...
  69. HIGH FIELD MRI IN PARKINSONS DISEASE
    Jay Gorell; Fiscal Year: 1999
    ..We are committed to this work, which we believe offers hope for better understanding of PD, MSA, PSP and MPTP-parkinsonism, devastating neurological disorders. ..
  70. CASE CONTROL/STUDY OF PARKINSONS DISEASE IN THE ELDERLY
    Richard Mayeux; Fiscal Year: 1999
    ....
  71. Ethics of Control and Consent in Brain Stimulation for Parkinson Disease
    CYNTHIA M S KUBU; Fiscal Year: 2010
    ..in participants'considerations of control using Deep Brain Stimulation (DBS) for the treatment of Parkinson disease (PD) as a paradigm...
  72. ON-OFF MOOD CHANGE IN PARKINSONS DISEASE
    Kevin Black; Fiscal Year: 2000
    ....
  73. SIGNALING MECHANISMS IN DOPAMINE RECEPTOR SYNERGISM
    Yuan Luo; Fiscal Year: 2007
    ..is associated with the expression or progression of diverse neurological and psychiatric diseases, including Parkinson disease, dyskinesias, schizophrenia, drug addiction, and Tourette disorder...
  74. PARKINSON DISEASE PATHOPHYSIOLOGY--CSF MARKERS
    Peter LeWitt; Fiscal Year: 1992
    ..its clinical picture and brain pathology (loss of nigrostriatal dopaminergic projections) are distinctive, Parkinson Disease (PD) is associated with few biological markers that can be studied in life...
  75. EPIDEMIOLOGICAL RISK FACTORS FOR PARKINSONS DISEASE
    Jay Gorell; Fiscal Year: 2001
    ..This proposed work will be the most systematic study of lead as a risk factor for PD yet done, and can help in the understanding of the etiopathogenesis of the disease. ..
  76. Breath Test for Individualizing CD Therapy in Parkinson Disease
    David I Rosen; Fiscal Year: 2010
    ..a simple, office-based breath test that can be used to individualize and optimize carbidopa therapy in Parkinson disease. PUBLIC HEALTH RELEVANCE: The proposed research seeks to develop a simple, safe and non-invasive breath-..